Brii gets a Covid-19 antibody boost
But is there room for another antibody, given lacklustre sales and Regeneron’s dominance?
Arrowhead pause raises more questions about lung delivery
Animal toxicity findings with ARO-ENaC come not long after Ionis’s similar setback.
US appetite for Covid-19 treatments remains undiminished
With a Darpin antiviral for treating Covid-19 Molecular Partners hopes to follow Vir’s regulatory path.
Roche and Vir add to the conflicting Covid-19 data
A win for Vir’s late-to-the-game antibody and another fail for Roche with Actemra show how developers are still feeling their way in Covid-19.
The bull case for Vir starts to unravel
Hopes for the highly valued biotech’s Covid-19 antibody dim before a more important look at the project’s potential.
Pandemic mutations prompt antibody collaborations
A trial testing a combination of Lilly and Vir antibodies is the latest attempt by developers to stay ahead of the virus that causes Covid-19.
